Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 10.0% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics Inc. (NASDAQ: NTLA) specializes in the development of CRISPR/Cas9 gene editing therapies for genetic diseases and experienced a significant upward movement in its stock price.

Why is Intellia Therapeutics, Inc. going up?

NTLA stock is up 10.0% on Feb 19, 2025 16:36

• The stock's positive momentum may be linked to Wall Street analysts forecasting a potential 422.41% rally, reflecting optimism for the company's future performance.
• Despite legal challenges and shareholder concerns, investors seem positive about Intellia Therapeutics Inc.'s long-term prospects and the efficacy of its gene editing treatments, driving the stock's upward trajectory.
• Investor sentiment appears to be more focused on the optimistic outlook provided by analysts rather than short-term legal issues, fueling the bullish movement in NTLA shares.
• The approaching investor deadline appears to have stimulated buying interest in anticipation of favorable developments or outcomes for Intellia Therapeutics Inc.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - Intellia Therapeutics ( NASDAQ:NTLA )

Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Intellia To Contact Him Directly To Discuss Their Options

https://www.benzinga.com/pressreleases/25/02/g43817184/shareholder-reminder-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-intellia-ther

INTELLIA THERAPEUTICS, INC. ( NASDAQ: NTLA ) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Intellia Therapeutics, Inc. Investors of Upcoming Deadline - Intellia Therapeutics ( NASDAQ:NTLA )

NEW YORK, Feb. 18, 2025 ( GLOBE NEWSWIRE ) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Intellia Therapeutics, Inc. NTLA? Did you purchase your shares between July 30, 2024 and January 8, 2025, inclusive? Did you lose money in your investment in Intellia Therapeutics, Inc.?

https://www.benzinga.com/pressreleases/25/02/g43777739/intellia-therapeutics-inc-nasdaq-ntla-deadline-alert-bernstein-liebhard-llp-reminds-intellia-thera

INTELLIA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Intellia Therapeutics, Inc. and Encourages Investors to Contact the Firm - Intellia Therapeutics ( NASDAQ:NTLA )

NEW YORK, Feb. 14, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc. ( "Intellia" or the "Company" ) NTLA in the United States District Court for ...

https://www.benzinga.com/pressreleases/25/02/g43753269/intellia-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-agains

Does Intellia Therapeutics ( NTLA ) Have the Potential to Rally 422.41% as Wall Street Analysts Expect?

The mean of analysts' price targets for Intellia Therapeutics (NTLA) points to a 422.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

https://www.zacks.com/stock/news/2416274/does-intellia-therapeutics-ntla-have-the-potential-to-rally-42241-as-wall-street-analysts-expect

INTELLIA THERAPEUTICS, INC. ( NASDAQ: NTLA ) INVESTOR ALERT: Investors With Large Losses in Intellia Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights - Intellia Therapeutics ( NASDAQ:NTLA )

NEW YORK, Feb. 12, 2025 ( GLOBE NEWSWIRE ) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors ( the "Class" ) who purchased or acquired the securities of Intellia Therapeutics, Inc. ( "Intellia" or the "Company" ) NTLA ...

https://www.benzinga.com/pressreleases/25/02/g43674576/intellia-therapeutics-inc-nasdaq-ntla-investor-alert-investors-with-large-losses-in-intellia-thera

Trending Today

Maker ($MKR) Crypto Forecast: Up 5.1% Today

Sonic (prev. FTM) ($S) Crypto Forecast: Up 5.1% Today

Golem ($GLM) Crypto Forecast: Up 31.6% Today

Optimism ($OP) Crypto Forecast: Up 5.6% Today

MANTRA ($OM) Crypto Forecast: Up 10.9% Today

NEAR Protocol ($NEAR) Crypto Forecast: Down 5.1% Today

Memecoin ($MEME) Crypto Forecast: Up 5.7% Today

Ethereum ($ETH) Crypto Forecast: Up 5.1% Today

Pepe ($PEPE) Crypto Forecast: Up 5.0% Today

Ethena ($ENA) Crypto Forecast: Down 6.0% Today

Intellia Therapeutics, Inc. Price History

22.00.2025 - NTLA Stock was up 5.2%

• The bullish movement in NTLA's stock price could be attributed to the announcement of dosing the first patient in the HAELO Phase 3 study of NTLA-2002, showcasing progress in their investigational CRISPR gene editing treatment for Hereditary Angioedema.
• Despite recent negative news causing a 21% drop in NTLA's stock price, the positive development of dosing the first patient in a crucial study may have instilled confidence in investors, leading to the bullish movement.
• The market's reaction suggests that investors are optimistic about the potential success of NTLA's gene editing treatments, overshadowing recent setbacks and positioning the company favorably in the biotech sector.

19.01.2025 - NTLA Stock was up 10.0%

• The stock's positive momentum may be linked to Wall Street analysts forecasting a potential 422.41% rally, reflecting optimism for the company's future performance.
• Despite legal challenges and shareholder concerns, investors seem positive about Intellia Therapeutics Inc.'s long-term prospects and the efficacy of its gene editing treatments, driving the stock's upward trajectory.
• Investor sentiment appears to be more focused on the optimistic outlook provided by analysts rather than short-term legal issues, fueling the bullish movement in NTLA shares.
• The approaching investor deadline appears to have stimulated buying interest in anticipation of favorable developments or outcomes for Intellia Therapeutics Inc.

10.00.2025 - NTLA Stock was down 8.6%

• NTLA's stock fell after announcing a strategic reorganization and significant job cuts, signaling potential internal challenges and restructuring efforts that investors might view as concerning.
• The inducement grants to new employees, while a positive sign for growth and talent acquisition, may not have been enough to offset the negative sentiment caused by the workforce reduction news.
• The market's reaction suggests that investors are closely monitoring the company's operational changes and future prospects, leading to a bearish trend in the stock price.

08.00.2025 - NTLA Stock was down 7.8%

• The downturn in NTLA stock might be attributed to profit-taking by investors following a recent uptrend.
• The recent announcement of inducement grants could have been seen as share dilution, prompting a sell-off.
• Investor wariness regarding regulatory policies on gene editing technologies could be adversely affecting the stock.
• In general, the current downward trend could be a short-term adjustment within the context of a promising industry outlook.

14.01.2025 - NTLA Stock was up 10.7%

• Analysts have a positive outlook on Intellia Therapeutics, with an average price target indicating a notable upside potential for the stock.
• The company is currently involved in several class action lawsuits from shareholders over alleged misrepresentations regarding a Phase 1/2 study, which may have initially impacted the stock's decline.
• The market's upbeat response today could be due to investors perceiving these legal issues as temporary obstacles, bolstering confidence in the company's future prospects.
• Despite the legal challenges, the optimistic sentiments from both analysts and investors seem to be fueling the bullish trend in Intellia Therapeutics' stock price.

18.01.2025 - NTLA Stock was up 5.9%

• Factors contributing to the bullish movement in NTLA:
• Analysts' optimistic price targets foresee significant upside potential.
• Analysts raising earnings estimates despite class action lawsuits may have boosted investor confidence.
• The potential 422.41% rally as projected by Wall Street analysts likely attracted buying interest.
• In conclusion, despite challenges and alerts, analysts' positive outlook on Intellia Therapeutics' growth potential likely drove today's bullish movement.

10.00.2025 - NTLA Stock was down 6.4%

• The stock of Intellia Therapeutics (NTLA) displayed bearish movement during the trading session.
• Speculations attribute this shift to strategic reorganization plans, job cuts, and a significant reduction in workforce by 27% projected for 2025.
• Concerns arise among investors regarding the restructuring's potential influence on the company's future growth and development of advanced projects.
• Market reactions reflect uncertainties surrounding the company's strategic direction and the consequences of disclosed inducement grants per Nasdaq Listing Rule 5635 (c)(4).

16.00.2025 - NTLA Stock was down 6.2%

• NTLA experienced a bearish movement possibly due to financial and strategic updates that fell short of expectations, prompting selling by investors.
• An announcement about a strategic reorganization and significant job cuts planned for 2025 raised concerns about future growth potential.
• Despite notable trading activities in the biotech sector by Ark Invest, there was no increase in their stake in NTLA, which might suggest reduced confidence in the company.
• The focus on late-stage programs targeting specific genetic diseases led to uncertainties regarding the timeline and success of these therapies, influencing investor sentiment in a negative way.

16.00.2025 - NTLA Stock was down 5.0%

• Recent significant trades in Intellia Therapeutics by a prominent investor might have initially boosted confidence among investors. However, news of the company's workforce reduction of over a quarter may have raised concerns about its future outlook.
• The company's strategic priorities for 2025, focusing on advancing late-stage programs, were overshadowed by the negative impact of the announced layoffs.
• The strategic restructuring and job cuts outlined for 2025 could indicate potential challenges ahead, contributing to the bearish trend in the stock price.

30.00.2025 - NTLA Stock was up 6.0%

• Despite a bearish outlook from an analyst, Intellia Therapeutics (NTLA) exceeded expectations and showed an upward surge.
• The market movement could be linked to promising advancements in NTLA's pipeline, suggesting progress in their CRISPR/Cas9 therapies.
• Investor optimism about NTLA's future prospects likely led to increased buying pressure and a rise in the stock price.
• The analyst's downgrade did not shake investors' confidence in Intellia Therapeutics, demonstrating robust support for the company's innovative approaches in genetic disease treatments.

14.01.2025 - NTLA Stock was up 11.8%

• The uptrend in NTLA's stock price could be linked to the securities class action lawsuits it is currently facing. Despite these legal challenges, investors seem hopeful about the company's ability to navigate through them and pursue its groundbreaking work in gene editing therapies.
• Some investors may consider the lawsuits as temporary obstacles that could ultimately result in long-term value creation for the company, explaining the optimistic market sentiment.
• NTLA's resilience in the face of legal scrutiny reflects investors' trust in the company's technology and future prospects, contributing to today's bullish movement in the stock.

23.00.2025 - NTLA Stock was up 5.8%

• Intellia Therapeutics announced the dosing of the first patient in the pivotal Phase 3 study for NTLA-2002, a treatment for hereditary angioedema. This positive development likely contributed to the bullish movement.
• Despite a recent 21.6% decline in the stock price due to strategic announcements, the initiation of a significant study has rejuvenated investor confidence in the company's future prospects.
• The market's positive reaction to the news reflects investors' optimism about Intellia's innovative gene editing technologies and potential breakthroughs in treating genetic disorders.